by Dr. Ed Weber | Jul 29, 2026 | PCa Commentary
Any man who has undergone androgen deprivation therapy – ADT – to suppress his prostate cancer will have suffered some or all the associated adverse effects of diminished testosterone: fatigue, hot flushes, cognitive decline, bone density loss, erectile...
by Dr. Ed Weber | Jun 9, 2026 | PCa Commentary
After a biopsy diagnosis of prostate cancer, supported by an MRI and Ga 68PET/CT, if the disease is localized to the prostate, the initial decision is whether to treat the cancer with surgery or radiation therapy or defer to active surveillance. Treatment is...
by Dr. Ed Weber | May 26, 2026 | PCa Commentary
Following primary therapy with surgery or radiation in men with high-intermediate-risk and high-risk prostate cancer at diagnosis, the disease will recur in 20 – 30%. The recurrences may involve a small number of metastatic lesions, <5 sites or a few more....
by Dr. Ed Weber | Apr 8, 2026 | PCa Commentary
Identifying mutations in the DNA Damage Repair (DDR) genes BRCA 1 & 2, ATM, PALB2 and CHEK2 carries clinical significance and opportunities. These genes (and several others) cooperate in repairing single-and double-strand DNA breaks, that if not corrected, impair...
by Dr. Ed Weber | Feb 19, 2026 | PCa Commentary
Androgen Deprivation Therapy, (ADT) for Treatment of Prostate Cancer can lead to an unseen liability, loss of bone density or osteoporosis. Prostate cancer suppression with Lupron and other testosterone lowering agents (ADT) has been long-recognized and widely...
